October 26, 2017
New data presented at EACS 2017 suggested that the investigational REV inhibitor ABX464 might reduce the viral reservoir in a study that included a treatment interruption.1
The ABX464-004 study randomised (3:1) 30 participants on stable ART (CD4 nadir >350) who had been taking boosted darunavir monotherapy for at least 8 weeks to either add ABX464 (mainly 150 mg) or matched placebo for 28 days, after which all treatment was stopped. Full ART was restarted if viral load rebounded to >1000 copies/mL.
The impact on viral reservoir was measured by total HIV DNA in PBMCs with response defined as minimum reduction of 50 copies/million PBMCs and >25% decrease in HIV DNA copies.
Baseline characteristics included median duration of HIV infection of 10.2 years with median 5.6 years on ART.
In the 15 subjects with validated viral DNA results, 8/15 (53%) of the active group reported significant reductions (mean change of -38% (95%CI: -27% to -67%], with a mean decrease of 185 copies/million PBMCs (95%CI: -434 to -82) compared to no responders in the placebo group (0/4).
However, there were no differences between groups in time to viral rebound after stopping ART: mean 13 vs 14 days for ABX464 vs placebo groups respectively.
Tolerability was good with no serious side effects reported in the treatment group.
ABX464 blocks the end stages of viral assembly. Results on antiviral efficacy from an earlier phase 2a dose-ranging study in 80 treatment-naive participants in Thailand reported modest antiviral activity (~0.5 log copies/mL) but only in 4/6 people using the highest 150 mg dose (with no responses in 2/6).2
Future studies are planned to use ABX464 with triple therapy ART using longer treatment with ABX464 (64 days) (study 005), in people suppressed in chonic infection (study 006) and those treated in acute infection (study 007).
[Note from TheBodyPROD.com: This article was originally published by HIV i-Base on Oct. 26, 2017. We have cross-posted it with their permission.]
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|The Future of 2-Drug Regimens for People With HIV|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.